Effects of Intranasal Oxytocin and Vasopressin on Social Behavior and Decision Making

• Register: ClinicalTrials.gov
• Last refreshed on: 24 August 2015
• Main ID: NCT02526914
• Date of registration: 14/08/2015
• Prospective Registration: Yes
• Primary sponsor: David Mankuta
• Public title: Effects of Intranasal Oxytocin and Vasopressin on Social Behavior and Decision Making
• Scientific title: Effects of Intranasal Oxytocin and Vasopressin on Social Behavior and Decision Making
• Date of first enrolment: October 2015
• Target sample size: 432
• Recruitment status: Not yet recruiting
• URL: https://clinicaltrials.gov/show/NCT02526914
• Study type: Interventional
• Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science
• Phase: N/A

Countries of recruitment

Israel

Contacts

• Name: David Mankuta, MD

• Name: David Mankuta, MD

• Name: David Mankuta, MD
• Affiliation: Hadassah University Medical Organization

Key inclusion & exclusion criteria

Inclusion Criteria:

• healthy controls

Exclusion Criteria:

- Past or present psychiatric, neurological, endocrinological or severe chronic medical
illness.

- Use of medications or drugs that would interfere with study results. This includes
steroids, medications for psychiatric symptoms like anxiety or depression,
stimulants, and medications for high blood pressure. Participants will be asked to
tell the investigators of any medications or drugs that they are taking. The
investigators will consider the drug interactions with oxytocin and vasopressin prior
to study, and participants will not be able to participate in the study if the drug
interactions could be dangerous.

- history of drug or alcohol addiction

- Pregnancy or Nursing Status: Because of the risk to an unborn fetus or infant, women
who are pregnant or nursing are excluded from this protocol. All females will have a
pregnancy test performed no more than 24 hours before each drug administration and
will not be able to participate if the pregnancy test is positive.



Age minimum: 21 Years
Age maximum: 35 Years
Gender: Both

Health Condition(s) or Problem(s) studied

Healthy

Intervention(s)

Drug: Intranasal Oxytocin

Drug: Intranasal placebo

Drug: Intranasal vasopressin

Primary Outcome(s)

Preferences for competitive vs cooperative compensations and monetary allocations as measured by participants monetary allocations and compensation choice [Time Frame: approximately 45 minutes after intranasal administration of vasopressin, oxytocin, or placebo]

Secondary Outcome(s)

Bargaining performance as assessed by participants' earnings in bargaining compensation [Time Frame: approximately 45 minutes after intranasal administration of vasopressin, oxytocin, or placebo]

Social value orientation as measured by monetary allocations preferences [Time Frame: approximately one hour and fifteen minutes after administration of oxytocin, vasopressin or placebo]

Monetary offers in public goods game [Time Frame: approximately 45 minutes after intranasal administration of vasopressin, oxytocin, or placebo]

Fear of negative evaluation (FNE) as measured by self reporting [Time Frame: approximately one hour and fifteen minutes after administration of oxytocin, vasopressin or placebo]

Willingness to compete as measured by participants compensation choice. [Time Frame: approximately 45 minutes after intranasal administration of vasopressin, oxytocin, or placebo]

Negative hypothesis test strategy usage on Wason's-rule-discovery-task after exposure to trustworthy/untrustworthy face [Time Frame: approximately 45 minutes after intranasal administration of vasopressin, oxytocin, or placebo]

Positive and negative affect scale (PANAS) [Time Frame: approximately one hour and fifteen minutes after administration of oxytocin, vasopressin or placebo]

Monetary offers in all pay auction [Time Frame: approximately 45 minutes after intranasal administration of vasopressin, oxytocin, or placebo]

Redistribution preferences as measured by participants' tax rate determination [Time Frame: approximately 45 minutes after intranasal administration of vasopressin, oxytocin, or placebo]

Secondary ID(s)

Hadassah Medical Organization

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

Hebrew University of Jerusalem